Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals
Source: EQS
It is expected to become the world's first heavyweight iteration of a major item to be launched on the marketAccording to the announcement, the iterative serum-free rabies vaccine has completed the preliminary work for marketing registration, and has undergone process verification in the GMP workshop that meets the marketing scale and quality requirements. The pre-inspection results for drug registration meet the quality standards. The company will submit the application for listing registration of the product as soon as possible. Completely unlike the existing Vero cell rabies vaccine containing serum and human diploid rabies vaccine containing serum, the iterative serum-free rabies vaccine is an iterative product. Animal serum residues in vaccine products are one of the important factors leading to adverse reactions such as allergies in vaccinated populations, and the iterative serum-free rabies vaccine developed by the Company does not contain animal serum, which significantly improves safety and reduces the probability of adverse reactions. According to the company's 2024 interim report, with respect to rabies vaccines in This year is a year of intensive application for Aimi vaccines. Three heavyweight single-product vaccines, including iterative serum-free rabies vaccine, are accelerating their application for listing. The accelerated launch process of new products is expected to become a new performance growth point for the company. Hashtag: #AIM The issuer is solely responsible for the content of this announcement. News Source: 艾美疫苗股份有限公司
|